Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The advent of de novo proteins for cancer immunotherapy

1 May 2020

Abstract excerpt

Engineered proteins are revolutionizing immunotherapy, but advances are still needed to harness their full potential. Traditional protein engineering methods use naturally existing proteins as a starting point, and therefore, are intrinsically limited to small alterations of a protein's natural structure and function. Conversely, computational de novo protein design is free of such limitation, and can produce a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to CAR-T cell therapy research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32371023
DOI: 10.1016/j.cbpa.2020.02.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The advent of de novo proteins for cancer immunotherapyPMID 32371023Read ↗

<i>De novo</i> protein design enables precise induction of functional antibodies <i>in vivo</i>Semantic proximity Read ↗

Machine-guided dual-objective protein engineering for deimmunization and therapeutic functionsSemantic proximity Read ↗

<i>De novo</i> and scaffold-based design of GDF15 binders for cancer cachexia diagnostics and therapeuticsSemantic proximity Read ↗

Machine-Guided Dual-Objective Protein Engineering for Deimmunization and Therapeutic FunctionsSemantic proximity Read ↗

<i>De novo</i> design of stable proteins that efficaciously inhibit oncogenic G proteinsSemantic proximity Read ↗

De novo designed pMHC binders facilitate T cell induced killing of cancer cellsSemantic proximity Read ↗

Insights into the binding recognition and computational design of IL-2 muteins with enhanced predicted binding affinity to the IL-2 receptor α.Semantic proximity Read ↗

Integrating Computational Design and Experimental Approaches for Next-Generation BiologicsSemantic proximity Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

Computer-guided design of Z domain peptides with improved inhibition of VEGFSemantic proximity Read ↗

<i>In silico</i> evolution of protein binders with deep learning models for structure prediction and sequence designSemantic proximity Read ↗

Recent advances in (therapeutic protein) drug developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.